Granules India Limited is a vertically integrated pharmaceutical company specializing in active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), and finished dosage formulations (FDFs). Founded in 1991, the company has built a strong global presence by supplying high-quality pharmaceutical products to regulated and emerging markets across more than 80 countries. Granules focuses on high-volume therapeutic categories including pain management, cardiovascular diseases, diabetes, and anti-infectives. The company’s integrated manufacturing model enables cost-efficient production while ensuring consistent product quality and regulatory compliance. Granules operates multiple manufacturing facilities approved by leading global regulatory authorities, including the US FDA and EMA. Continuous investments in research, product development, and manufacturing automation have strengthened its competitive position within the global generic pharmaceutical industry. Through operational excellence, sustainability initiatives, and customer-focused innovation, Granules continues to expand its international footprint while supporting affordable healthcare worldwide.
NSE: GRANULES | BSE: 532482
Hyderabad, Telangana, India
~7,500 employees
